Skip to main content

The Role of NIH in Drug Development Innovation and Its Impact on Patient Access Proceedings of a Workshop (2020) / Chapter Skim
Currently Skimming:

Appendix B: Workshop Agenda
Pages 81-86

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 81...
... Appendix B Workshop Agenda WEDNESDAY, JULY 24, 2019 8:00 am Registration 8:45 am Welcome and Workshop Overview Jeff Bingaman, J.D., Planning Committee Chair 9:00 am SESSION 1: Keynote Address Moderator: Jeff Bingaman, J.D., Former U.S. Senator, New Mexico Overview of the Translational Research Landscape •  Christopher Austin, M.D., National Center for Advancing Translational Sciences, National Institutes of Health (NIH)
Read the entire page →
From page 82...
... 82 THE ROLE OF NIH IN DRUG DEVELOPMENT INNOVATION 10:15 am SESSION 2: Federal Funding for Biomedical Research and Its Contributions to New Drug Development and Commercialization Moderator: Amitabh Chandra, Ph.D., Harvard University Session Objective: To discuss the impacts of publicly funded bio medical research and ways to better track, quantify, and document ­ NIH investments that lead up to drug commercialization Food and Drug Administration (FDA) Initiatives to Advance Drug Development Innovation •  Janet Woodcock, M.D., Center for Drug Evaluation and Research, FDA The Public-Sector Role in Drug Development • Bhaven Sampat, Ph.D., Columbia University Gauging the Returns on Federally Funded Basic Research •  Danielle Li, Ph.D., Massachusetts Institute of Technology Sloan School of Management Quantifying the Impact of NIH Funding on Pharmaceutical Innovation • Margaret Blume Kohout, Ph.D., Gettysburg College Panel Discussion 12:00 pm Lunch Break 1:00 pm SESSION 3: Patent and Technology Transfer Policies in Promoting the Development and Commercialization of NIH-Conducted and -Funded Medical Research Moderator: Stephen Merrill, Ph.D., Senior Fellow and former executive director, Center for Innovation Policy at Duke Law Session Objective: To discuss the current state of technology transfer agreements and licensing, and models for spurring drug innovation
Read the entire page →
From page 83...
... Department of Defense (DoD) to Advance Drug Development Innovation • Terry Rauch, Ph.D., M.P.H., M.B.A., DoD Collaborating to Accelerate Medical Product Development • Lynn Hudson, Ph.D., Critical Path Institute
Read the entire page →
From page 84...
... 84 THE ROLE OF NIH IN DRUG DEVELOPMENT INNOVATION Strategies to Aid Repurposing of Compounds for Secondary Uses • Christine Colvis, Ph.D., National Center for Advancing Translational Sciences, NIH Infrastructure in Drug Development Innovation • David Dilts, Ph.D., M.B.A., Vanderbilt University and Oregon Health & Science University Panel Discussion 5:00 pm Wrap-Up and Open Discussion Ameet Sarpatwari, Ph.D., J.D., Harvard Medical School and Brigham and Women's Hospital 5:30 pm Adjourn Day 1 THURSDAY, JULY 25, 2019 8:00 am Registration 8:30 am SESSION 5: Drug Pricing and Innovative Financing and Business Models Moderator: Patricia Danzon, Ph.D., University of Pennsylvania Session Objective: To discuss the economic implications of escalating drug costs and explore new ideas and opportunities, potential business models, and financing structures to accelerate drug discovery and development Drug Pricing: The Components • Patricia Danzon, Ph.D., University of Pennsylvania Consumer Perspective on Recent Prescription Drug Price Trends • Leigh Purvis, M.P.A., AARP Public Policy Institute Innovative Drugs: Access to Medicaid Beneficiaries • Doug Wirth, M.S.W., Amida Care
Read the entire page →
From page 85...
... Strategies and Policies Available to Bring About Transformative Reductions in the Increasing Prices of Drugs • Aaron Kesselheim, M.D., J.D., M.P.H., Harvard Medical School and Brigham and Women's Hospital Panel Discussion 12:30 pm Wrap-Up and Adjourn
Read the entire page →

Key Terms

  • development innovation
  • critical path
  • terry rauch
  • medical product
  • path institute

  • advance drug
  • accelerate medical
  • panel discussion
  • lynn hudson
  • medical school

  • harvard medical
  • increasing prices
  • product development
  • policies available
  • transformative reductions


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.